{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"PFS is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphomas (iNHL) disease progression or death from any cause. Definitive iNHL disease progression is progression based on standard criteria. PFS was to be assessed by an independent review committee (IRC).","groups":[{"description":"Idelalisib 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions) + rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"OG000","title":"Idelalisib + Bendamustine + Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions) + rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"OG001","title":"Placebo + Bendamustine + Rituximab"}],"populationDescription":"Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.","reportingStatus":"POSTED","title":"Progression-free Survival (PFS)","type":"PRIMARY"}